Enhancing the efficacy of cancer vaccines in urologic oncology: new directions.

Nat Rev Urol

Department of Urology, Prostate Disease Center, University of Florida College of Medicine, Gainesville, FL 32610-0247, USA.

Published: October 2009

Immunotherapeutic interventions have long been utilized in urologic oncology for the treatment of metastatic renal cell or superficial transitional cell carcinoma. Most recently, the first active specific immunotherapeutic approach, a cancer vaccine, has passed the final phase of human testing and its approval by the FDA is pending. However, evidence suggests that the full protective and therapeutic potential of cancer vaccines has not yet been achieved. Through multiple mechanisms, tumors promote conditions in the tumor-bearing host that mitigate or even eliminate the vaccine-induced antitumor response. Restoration of the impaired immune function is, therefore, imperative for achieving optimum vaccine efficacy. Targeted pharmacological interventions are capable of overcoming tumor-mediated immunosuppression, and thereby enable cancer vaccination to reach its full therapeutic potential.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2009.177DOI Listing

Publication Analysis

Top Keywords

cancer vaccines
8
urologic oncology
8
therapeutic potential
8
enhancing efficacy
4
cancer
4
efficacy cancer
4
vaccines urologic
4
oncology directions
4
directions immunotherapeutic
4
immunotherapeutic interventions
4

Similar Publications

Cancer immunotherapy, which leverages immune system components to treat malignancies, has emerged as a cornerstone of contemporary therapeutic strategies. Yet, critical concerns about the efficacy and safety of cancer immunotherapies remain formidable. Nanotechnology, especially polymeric nanoparticles (PNPs), offers unparalleled flexibility in manipulation-from the chemical composition and physical properties to the precision control of nanoassemblies.

View Article and Find Full Text PDF

Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates.

Mol Ther

January 2025

Department of Biological Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA, 02139; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Cambridge, MA, USA, 02139; Department of Chemical Engineering, Massachusetts Institute of Technology; Cambridge, MA, USA, 02139; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University; Cambridge, MA, USA, 02139; Howard Hughes Medical Institute; Chevy Chase, MD, USA, 20815; Department of Materials Science of Engineering; Massachusetts Institute of Technology; Cambridge, MA, USA, 02139. Electronic address:

mRNA delivered using lipid nanoparticles (LNPs) has become an important subunit vaccine modality, but mechanisms of action for mRNA vaccines remain incompletely understood. Here, we synthesized a metal chelator-lipid conjugate enabling positron emission tomography (PET) tracer labeling of LNP/mRNA vaccines for quantitative visualization of vaccine trafficking in live mice and non-human primates (NHPs). Following i.

View Article and Find Full Text PDF

Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach.

Int J Mol Sci

January 2025

State Key Laboratory of Developmental Biology of Freshwater Fish, Engineering Research Center of Polyploid Fish Reproduction and Breeding of the State Education Ministry, College of Life Sciences, Hunan Normal University, Changsha 410081, China.

In recent years, circular RNAs (circRNAs) have garnered significant attention due to their unique structure and function, positioning them as promising candidates for next-generation vaccines. The circRNA vaccine, as an RNA vaccine, offers significant advantages in preventing infectious diseases by serving as a vector for protein expression through non-canonical translation. Notably, circRNA vaccines have demonstrated enduring antigenic expression and generate a larger percentage of neutralizing antibodies compared to mRNA vaccines administered at the same dosage.

View Article and Find Full Text PDF

Roles of Mature Domain Targeting Signals (MTSs) for Protein Translocation and Secretion in .

Int J Mol Sci

December 2024

Institute of Food Technology, Department of Food Science and Technology, BOKU University, 1190 Vienna, Austria.

is a potential bacterial cell factory to develop delivery systems for vaccines and therapeutic proteins. Much progress has been made in applications using engineered against, e.g.

View Article and Find Full Text PDF

An Overview of Zika Virus and Zika Virus Induced Neuropathies.

Int J Mol Sci

December 2024

Department of Entomology, Pennsylvania State University, University Park, PA 16802, USA.

Flaviviruses pose a major public health concern across the globe. Among them, Zika virus (ZIKV) is an emerging and reemerging arthropod-borne flavivirus that has become a major international public health problem following multiple large outbreaks over the past two decades. The majority of infections caused by ZIKV exhibit mild symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!